Pacira BioSciences, Inc.
About Pacira BioSciences, Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $726.4M
- Net income
- $7.0M
- Total assets
- $1.3B
- Market cap
- $895.2M
- Gross margin
- 79.4%
- Operating margin
- 2.6%
- Net margin
- 1.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $726.4M
- Cost of revenue
- $149.7M
- Gross profit
- $576.7M
- Operating expenses
- $557.5M
- Operating income
- $19.2M
- Income tax
- $9.8M
- Net income
- $7.0M
- EPS (basic)
- $0.16
- EPS (diluted)
- $0.16
Balance sheet
- Total assets
- $1.3B
- Current assets
- $548.0M
- Total liabilities
- $571.8M
- Current liabilities
- $120.6M
- Shareholders’ equity
- $693.1M
Cash flow
- Operating cash flow
- $152.0M
- Investing cash flow
- $99.5M
- Financing cash flow
- -$369.6M
- Net cash flow
- -$118.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $895.2M
- P/E ratio
- 142.9
- EPS (diluted)
- $0.16
- Shares outstanding
- 39.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 3, 2011
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $7.0M in FY2025.
- Revenue grew 69% from FY2020 to FY2025.
- Gross margin of 79.4%, net margin 1.0%.
- Trading 16% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 142.9.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Pacira BioSciences, Inc..
Write a review
News about Pacira BioSciences, Inc.
News & sentiment via Polygon.io
